HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) MARKET ANALYSIS

Hematopoietic Stem Cell Transplantation (HSCT) Market, By Transplant Type (Allogeneic, Autologous), By Indication (Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Hodgkin lymphoma (HL), Non-Hodgkin Lymphoma (NHL), Multiple Myeloma (MM), Others), By Application (Bone Marrow Transplant (BMT), Peripheral Blood Stem Cells Transplant (PBSCT), Cord Blood Transplant (CBT)), By End User (Hospitals, Specialty Clinics, Others), By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)

Published In : Aug 2023
Code : CMI1250
Pages :208
Formats :
Excel and PDF
Industry : Biotechnology

Regional Analysis

Global Hematopoietic Stem Cell Transplantation (HSCT) Market - Regional Analysis

Among regions, North America is estimated to hold a dominant position in the global hematopoietic stem cell transplantation (HSCT) market over the forecast period. North America is estimated to hold 33.5% of the market share in 2023. The global hematopoietic stem cell transplantation (HSCT) market is expected to witness significant growth in the coming years due to increasing inorganic growth strategies such as mergers to expand their product portfolio in North America region. For instance, in May 2021, Jasper Therapeutics, Inc., a U.S. based biotechnology company focused on hematopoietic cell transplant therapies, announced the merger with Amplitude Healthcare Acquisition Corporation, a private life science company, to provide significant capital to accelerate the development of our two innovative programs: Jasper’s first-in-class clinical-stage anti-CD117 antibody transplant conditioning agent and, in parallel, our groundbreaking research stage Engineered Hematopoietic Stem Cell platform.

Hematopoietic stem cell transplantation (HSCT) market Report Snapshots